The downregulation of ADAMTS5 expression level in our Aβ group data was supported by previous study which demonstrated that ADAMTS4 and ADAMTS5 expressions were slightly under-expressed in case of AD which indicated the deficiency in the elimination of ECM in patients, which ultimately resulted in the accumulation of undesirable ECM compounds over time (Pehlivan et al., 2016). This evidence concerns the gene ADAMTS4 and Alzheimer disease.